RecruitingPhase 4NCT04781972

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Sponsor

Johns Hopkins University

Enrollment

30 participants

Start Date

Jul 27, 2021

Study Type

INTERVENTIONAL

Conditions

ADHD - Combined Type

Summary

The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.

Eligibility

Min Age: 6 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Methylphenidate and a drug called Placebo for people with adhd - combined type. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.